Biogen Inc.는 복잡한 신경학적 및 신경퇴행성 질환을 위한 치료제의 발견, 개발, 생산, 유통에 전념하는 선도적인 바이오테크 기업입니다. 이 회사의 확립된 포트폴리오에는 다발성 ...
임뮤텝(Immutep, ASX:IMM) 주가가 INSIGHT-003 폐암 연구에서 긍정적인 전체 생존(Overall Survival) 데이터를 공개한 뒤 30% 급등하며 eftilagimod alfa 치료에 대한 기대가 다시 커졌다. 이는 앞서 TACTI-004 시험이 무용성(futility) 분석 결과로 중단된 데 따른 것이다. 회사는 곧 더 많은 결과를 공개할 계획이며, TACTI-004 시험이 기대에 미치지 못한 이유를 조사하고 있다.
LGT Fund Management Co Ltd.는 1분기 동안 엔브리지(Enbridge Inc, NYSE: ENB)에 신규 지분을 매입했다. 187,966주를 약 1,018만 달러 규모로 사들였으며, 이 움직임은 엔브리지에 대한 대규모 기관 투자자들의 관심이 확대되는 더 큰 흐름의 일부다. 뱅가드(Vanguard)와 노르게스 은행(Norges Bank) 같은 주요 투자자들도 지분을 늘리거나 신규 포지션을 개시하고 있다. 엔브리지는 최근 주당 $0.71의 강한 분기 실적을 발표해 애널리스트 예상치를 상회했으며, 주당 $0.97의 분기 배당금도 선언했는데, 이는 연환산 기준 수익률 7.1%에 해당한다.
AAIC 2026에서 발표된 새로운 임상 데이터에 따르면 LEQEMBI®(lecanemab) 피하 자가주사기(SC-AI) 제형은 조기 알츠하이머병에서 정맥(IV) 투여와 비교해 유사한 효능과 안전성을 제공한다. 결과는 주 1회 500mg SC-AI가 승인된 IV 요법과 유사한 약물 노출을 달성했으며, 이는 유사한 임상적 결과에 대한 기대를 뒷받침한다. 환자 및 돌봄 파트너 설문에서도 피하 제형에 대한 높은 만족도와 편의성이 확인되어, 장기 질환 관리에 대한 잠재력을 강화한다.
에자이 주식회사(Eisai Co., Ltd.)와 바이오젠 주식회사(Biogen Inc.)는 알츠하이머병 학회 국제학술대회 2026(Alzheimer’s Association International Conference 2026)에서 새로운 데이터를 발표하며, 조기 알츠하이머병 환자를 위한 LEQEMBI 피하 자가주사기(SC-AI)가 정맥(IV) 제형과 비교해 동등한 효능과 안전성을 제공한다고 밝혔다. SC-AI 제형은 환자 체중 범주 전반에서 유사한 약물 노출과 임상적 결과를 제공하며, 여기에 집에서 편리하게 투여할 수 있다는 추가 이점이 있다. 피하 옵션에 대한 환자 만족도도 높아, 치료 접근성과 장기 질환 관리 개선 가능성을 보여준다.
아르젠엑스(Argenx)는 자가면역 질환에 대한 항체 기반 치료를 전문으로 하는 바이오텍 기업으로, 유럽 브뤼셀(Euronext Brussels)과 나스닥(Nasdaq)에 이중 상장돼 글로벌 바이오텍 중 ‘고위험·고수익’ 구간에 자리하고 있다. 이 회사는 정밀의학과 만성 자가면역 질환을 위한 장기 치료에 집중함으로써 항체 공학 프로그램 파이프라인을 통해 반복 매출 흐름을 창출하는 것을 목표로 한다. 투자자들은 임상시험 결과, 규제 승인, 상용화 전략을 주시하며, 충족되지 않은 의료 수요를 겨냥한 혁신 치료제에서 기대할 수 있는 잠재적 보상을 염두에 두고 이러한 위험을 균형 있게 평가한다.
임뮤텝(Immutep, ASX:IMM) 주가가 INSIGHT-003 폐암 연구에서 긍정적인 전체 생존(Overall Survival) 데이터를 공개한 뒤 30% 급등하며 eftilagimod alfa 치료에 대한 기대가 다시 커졌다. 이는 앞서 TACTI-004 시험이 무용성(futility) 분석 결과로 중단된 데 따른 것이다. 회사는 곧 더 많은 결과를 공개할 계획이며, TACTI-004 시험이 기대에 미치지 못한 이유를 조사하고 있다.
LGT Fund Management Co Ltd.는 1분기 동안 엔브리지(Enbridge Inc, NYSE: ENB)에 신규 지분을 매입했다. 187,966주를 약 1,018만 달러 규모로 사들였으며, 이 움직임은 엔브리지에 대한 대규모 기관 투자자들의 관심이 확대되는 더 큰 흐름의 일부다. 뱅가드(Vanguard)와 노르게스 은행(Norges Bank) 같은 주요 투자자들도 지분을 늘리거나 신규 포지션을 개시하고 있다. 엔브리지는 최근 주당 $0.71의 강한 분기 실적을 발표해 애널리스트 예상치를 상회했으며, 주당 $0.97의 분기 배당금도 선언했는데, 이는 연환산 기준 수익률 7.1%에 해당한다.
AAIC 2026에서 발표된 새로운 임상 데이터에 따르면 LEQEMBI®(lecanemab) 피하 자가주사기(SC-AI) 제형은 조기 알츠하이머병에서 정맥(IV) 투여와 비교해 유사한 효능과 안전성을 제공한다. 결과는 주 1회 500mg SC-AI가 승인된 IV 요법과 유사한 약물 노출을 달성했으며, 이는 유사한 임상적 결과에 대한 기대를 뒷받침한다. 환자 및 돌봄 파트너 설문에서도 피하 제형에 대한 높은 만족도와 편의성이 확인되어, 장기 질환 관리에 대한 잠재력을 강화한다.
에자이 주식회사(Eisai Co., Ltd.)와 바이오젠 주식회사(Biogen Inc.)는 알츠하이머병 학회 국제학술대회 2026(Alzheimer’s Association International Conference 2026)에서 새로운 데이터를 발표하며, 조기 알츠하이머병 환자를 위한 LEQEMBI 피하 자가주사기(SC-AI)가 정맥(IV) 제형과 비교해 동등한 효능과 안전성을 제공한다고 밝혔다. SC-AI 제형은 환자 체중 범주 전반에서 유사한 약물 노출과 임상적 결과를 제공하며, 여기에 집에서 편리하게 투여할 수 있다는 추가 이점이 있다. 피하 옵션에 대한 환자 만족도도 높아, 치료 접근성과 장기 질환 관리 개선 가능성을 보여준다.
아르젠엑스(Argenx)는 자가면역 질환에 대한 항체 기반 치료를 전문으로 하는 바이오텍 기업으로, 유럽 브뤼셀(Euronext Brussels)과 나스닥(Nasdaq)에 이중 상장돼 글로벌 바이오텍 중 ‘고위험·고수익’ 구간에 자리하고 있다. 이 회사는 정밀의학과 만성 자가면역 질환을 위한 장기 치료에 집중함으로써 항체 공학 프로그램 파이프라인을 통해 반복 매출 흐름을 창출하는 것을 목표로 한다. 투자자들은 임상시험 결과, 규제 승인, 상용화 전략을 주시하며, 충족되지 않은 의료 수요를 겨냥한 혁신 치료제에서 기대할 수 있는 잠재적 보상을 염두에 두고 이러한 위험을 균형 있게 평가한다.
이오니스 파마슈티컬스(Ionis Pharmaceuticals, IONS)는 eplontersen(이플론터센)에 대한 3상 CARDIO-TTRansform 연구 실패 이후, 장중에 9%의 큰 폭 하락을 보이며 주간 하락률이 25%를 넘겼다. 핵심 가치 동력에 대한 이러한 임상 차질은 알라헤드(Arrowhead)와 사렙타(Sarepta) 같은 RNA 바이오텍 동종 기업에도 부정적인 영향을 미쳤지만, 경쟁사 알닐람(Alnylam)은 자사 약물 Amvuttra가 잠재적으로 이익을 줄 수 있다는 점에도 불구하고 더 작은 하락폭을 보았다. 이제 투자자들은 이오니스의 다가오는 촉매에 주목하고 있는데, 8월의 전체 시험 데이터와 9월 및 10월의 PDUFA 결정이 포함된다.
스톡 테라퓨틱스(Stoke Therapeutics, STOK)는 러셀 지수에서 최근 제외됐음에도 불구하고 3상 EMPEROR 연구의 등록을 완료한 뒤 조사를 받고 있다. 주가는 장기 및 단기에서 모두 큰 상승을 보였지만, 현재 주가 32.83달러는 45.10달러의 공정가치에 비해 저평가된 것으로 평가된다. 이는 매출의 빠른 확장과 마진 성장을 전제로 한 전망에 기반한다. 다만 이 밸류에이션은 EMPEROR 임상시험의 성공과 우호적인 규제 결과에 달려 있으며, 임상 및 실적 위험은 여전히 상당하다.
메소블라스트 리미티드(Mesoblast Limited)는 강한 리온실(Ryoncil) 순매출을 발표했는데, FY26 4분기에 3,600만 달러에 도달했고, 연간 전체(회계연도)로는 1억 1,500만 달러를 기록했다. 이는 미국의 높은 소아 수요에 힘입어 예상을 초과한 결과다. 실비우 이테스쿠(Silviu Itescu) 박사는 회사의 견고한 자본 포지션을 확인했으며, 이는 매출 성장과 신규 자금 조달로 뒷받침되어 라벨 확장 및 추가 제품 개발 같은 전략적 이니셔티브를 지원할 예정이다. 리온실은 12세 미만의 스테로이드 불응성 급성 이식편대숙주병(SR-aGvHD)에 대해 FDA가 승인한 유일한 치료제로, 추가적인 염증성 질환과 심부전 치료를 위한 rexlemestrocel-L 플랫폼에 대한 개발도 진행 중이다.
Denali Therapeutics will deliver the opening plenary address at the Alzheimer’s Association International Conference (AAIC) 2026, with CEO Ryan Watts discussing advancements in treating neurodegenerative diseases, particularly Alzheimer's. The company will highlight its proprietary TransportVehicle™ platform, which enables biologic therapies to cross the blood-brain barrier. Denali is also developing investigational therapies DNL628 and DNL921 targeting tau and amyloid beta, respectively, with clinical data expected in 2027.
Biogen's stock has declined following the disclosure of new charges that are expected to negatively impact its near-term earnings. The market reacted nervously to these financial pressures, as investors assess the potential effects on the company's profitability.
Denali Therapeutics (Nasdaq: DNLI) announced that co-founder and CEO Ryan Watts, Ph.D., will deliver the opening plenary address at the Alzheimer’s Association International Conference (AAIC) 2026 in London. He will discuss advancements in neurodegeneration biology, biomarkers, and Denali’s TransportVehicle™ technology, including its FDA-approved AVLAYAH™ therapy and investigational Alzheimer’s candidates DNL628 and DNL921. The presentation will highlight the company's focus on solving the challenge of brain delivery for neurodegenerative diseases.
Longboard Pharma (LBPH) stock tracks the company's efforts in developing therapies for neurological disorders, with valuation closely tied to clinical progress and funding capacity. As a clinical-stage biotechnology company, its success hinges on pipeline development, particularly its lead candidates targeting serotonin receptors for seizure disorders, and securing sufficient funding to advance trials. Investors closely watch clinical milestones and cash runway for this high-risk, high-reward segment of the biotech market.
X4 Pharmaceuticals, trading on Nasdaq as XFOR, is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for rare primary immunodeficiency and related disorders. Its strategy centers on niche medical needs and orphan drug designation, providing specialized treatments for conditions with limited options. The company's pipeline and clinical trial outcomes are critical for investors, as success in specific programs can significantly impact its valuation, particularly as it relies on external financing as a clinical-stage biotech.
The Degenerative Disc Disease (DDD) market is projected to grow significantly from $1.2 billion in 2025 to $7.2 billion by 2036, driven by advancements in regenerative therapies and rising prevalence. Key companies like Mesoblast and BioRestorative Therapies are making progress in clinical trials, with potential FDA approvals and market expansions anticipated. The market growth is fueled by an aging population and innovations in minimally invasive treatments, despite challenges like high costs and diagnostic complexities.
CervoMed Inc. has successfully completed enrollment in its Phase 2a clinical trial evaluating neflamapimod for the treatment of nonfluent variant primary progressive aphasia (nfvPPA). The trial, involving 25 participants, aims to assess the drug's safety, pharmacokinetics, and clinical effects, with initial clinical data expected in the first quarter of 2027. Despite a recent stock decline, analysts remain optimistic, seeing the company's stock as undervalued with price targets ranging from $9 to $27.
INmune Bio (NASDAQ: INMB) announced new Phase 2 imaging data for its drug XPro in early Alzheimer's disease, showing statistically significant changes in white matter myelin and concordant grey matter changes at Week 24. These findings, which support the biological activity of selective soluble TNF inhibition, will be presented at the Alzheimer’s Association International Conference (AAIC) 2026. The company believes these microstructural changes reflect early pathological processes of Alzheimer's and bolster confidence in XPro's potential.
Inventiva has appointed three independent directors, Dr. Barbara Krebs-Pohl, Dr. Anne Prener, and Camilla Soenderby, to its board, effective June 30, 2026. These appointments aim to strengthen expertise in clinical development, commercialization, and financial strategy as the biotech company prepares for the critical phase of its flagship project, lanifibranor. Annick Schwebig has departed from the board, with Chairman Mark Pruzanski highlighting the appointments' role in enhancing Inventiva's capabilities to realize lanifibranor's potential for NASH treatment.
Rep. Maria Elvira Salazar recently purchased shares of Brookfield Renewable Partners L.P. (NYSE:BEP) in amounts between $1,001 and $15,000 on June 3rd through her UBS brokerage account, according to a July 7th disclosure. The stock opened at $33.38, has a market cap of $10.07 billion, and a 4.7% dividend yield. Analysts currently hold a "Moderate Buy" consensus rating for BEP with an average price target of $38.00, despite some recent bearish rating cuts.
Biogen (BIIB) presented key strategic shifts at the 2024 Cantor Fitzgerald Global Healthcare Conference, focusing on shareholder returns, cost management, and a balanced pipeline strategy. The company is actively managing the gradual launch of Leqembi, anticipating further adoption with subcutaneous formulations and blood-based biomarkers. Biogen also addressed the competitive landscape with Lilly's donanemab and detailed ongoing regulatory review challenges for Leqembi in Europe.
Morgan Stanley has adjusted its price target for Biogen (BIIB) from $224 to $222. The firm has decided to maintain its Equalweight rating on the stock despite the slight reduction in the target price. This update reflects Morgan Stanley's current outlook on Biogen's valuation.
Congresswoman Maria Elvira Salazar recently made several notable trades, according to a congressional report. She sold Biogen Inc. stock and UnitedHealth Group Incorporated stock, while acquiring shares in Brookfield Renewable Partners L.P., Salesforce, Inc., and Voyager Technologies, Inc. These transactions provide insight into the investment strategies of a member of Congress.
Shares of Biogen Inc. (BIIB) fell 2.60% on Wednesday to $200.36, underperforming the broader market as the S&P 500 and Dow Jones Industrial Average also declined. This marked the third consecutive day of losses for the stock.
Congresswoman Maria Elvira Salazar recently made several notable financial transactions, including selling her shares in Biogen Inc. and UnitedHealth Group Incorporated. She also purchased stocks in Brookfield Renewable Partners L.P., Salesforce, Inc., and Voyager Technologies, Inc. These trades, detailed in a congressional report, provide insight into her investment strategy.
Moderna Inc. (MRNA) has appointed Michael McDonnell to its Board of Directors, bringing over 30 years of financial leadership experience from companies like Biogen and IQVIA Holdings. This move aims to strengthen Moderna's financial strategy and capital allocation as it advances its extensive mRNA product pipeline. Despite a recent stock decline, the company boasts a moderate GF Score™ of 58/100, reflecting strong financial health and growth potential, though profitability and insider selling remain areas of concern for investors.
Moderna (MRNA) announced the appointment of Michael McDonnell to its Board of Directors, effective July 8, 2026. McDonnell will also join the board's audit committee, bringing over three decades of financial leadership experience in life sciences and technology. This news comes as Moderna's shares retreat from a 52-week high.
Vertex Pharmaceuticals announced its plan to acquire Crinetics Pharmaceuticals for $10 billion, marking Vertex's largest acquisition to date. This deal allows Vertex to expand its drug portfolio beyond cystic fibrosis, gaining Crinetics' commercial drug Palsonify for acromegaly and other drug candidates. The acquisition reflects a broader trend of increased M&A activity in the pharmaceutical industry driven by patent expirations.
The article discusses how the Supreme Court's Amgen decision in 2023 significantly limited broad functional genus claims for antibody patents, shifting the landscape for biotech intellectual property. It explores various new patenting strategies emerging in response, including parental sequence claims, percentage sequence claims, means-plus-function claims, and the promising approach of using experimental data from paratope mapping with CDR-scanning technology. The author concludes that while IP coverage for antibodies has narrowed, these new strategies, particularly data-driven approaches, are likely to foster continued biotech innovation and a healthy balance of patent protection.
This article provides a quick overview of analyst ratings for Biogen (BIIB.US) as of today, July 8, 2026. The analyst forecast for the company's stock price falls within a range of $217 to $255.
BofA Securities has revised its price target for Biogen (BIIB) shares, increasing it to $217 from the previous $203. This adjustment was reported on July 8, 2026, at 08:56 am EDT by MT Newswires. Other analysts like Morgan Stanley, RBC Capital, Jefferies, HSBC, and Needham have also recently adjusted their price targets for Biogen.
Moderna Inc. has appointed Michael McDonnell, former Biogen Inc. CFO, to its board of directors and audit committee. The appointment comes as Moderna's stock is trading near its 52-week high, exhibiting significant year-to-date returns, although InvestingPro analysis suggests it is overvalued. McDonnell brings extensive financial and life sciences industry experience, which Moderna's leadership believes will be crucial as the company prepares for potential product launches.
Moderna, Inc. has appointed Michael McDonnell, former CFO of Biogen Inc., to its Board of Directors and Audit Committee, effective July 8, 2026. McDonnell brings over 35 years of financial leadership experience, including CFO roles at multiple public companies. His appointment is expected to strengthen Moderna's financial oversight as the company prepares for potential product launches and executes its long-term strategy.
Moderna Inc. has appointed Michael McDonnell, former Executive Vice President and CFO of Biogen Inc., to its board of directors and audit committee. McDonnell brings over 24 years of experience as a public company CFO in life sciences and technology. This appointment comes as Moderna's stock trades near its 52-week high, despite some valuation concerns.
Moderna has announced the appointment of Michael McDonnell, former Biogen Chief Financial Officer, to its Board of Directors and Audit Committee, effective July 8, 2026. McDonnell brings over 35 years of financial leadership and public company experience, which Moderna's leadership believes will be invaluable as the company advances its pipeline and prepares for future product launches. He will contribute his expertise in strategic growth, capital allocation, and building finance organizations to support Moderna's long-term strategy and mission in mRNA medicine.
Moderna (NASDAQ: MRNA) has appointed Michael McDonnell, former CFO of Biogen, to its Board of Directors, effective July 8, 2026. He will also serve on the Board’s Audit Committee, bringing over 35 years of financial leadership experience in the life sciences and technology sectors. This appointment is expected to strengthen Moderna's financial governance and aid in its pipeline advancement and long-term strategy.
Moderna has announced the appointment of Michael McDonnell, former Biogen Chief Financial Officer, to its Board of Directors and Audit Committee, effective July 8, 2026. McDonnell brings over 35 years of financial leadership and public company experience, which Moderna's leadership believes will be invaluable as the company advances its pipeline and prepares for potential product launches. He has previously held CFO roles at Biogen, IQVIA Holdings Inc., Intelsat S.A., MCG Capital Corporation, and EchoStar Communications Corporation.
Biogen (BIIB) reported Q1 2025 revenue of $2.43 billion, a 6.1% increase year-over-year, driven by growth in rare disease products, new product launches, and contract manufacturing, despite a decline in MS product revenue. Non-GAAP diluted EPS decreased by 18% to $3.02, impacted by a significant upfront payment to Stoke Therapeutics. The company provided full-year 2025 guidance, expecting total revenue to decline by a mid-single-digit percentage while actively pursuing pipeline advancements and cost-saving initiatives.
DelveInsight's "Multiple Myeloma Pipeline Insight, 2026" report highlights the extensive global effort to develop new therapies for Multiple Myeloma, with over 75 companies and 80+ treatments in various stages of development. Recent clinical trial advancements emphasize the efficacy of bispecific antibodies and CAR-T cell therapies, with regulatory approvals broadening treatment options, particularly for relapsed or refractory cases. The report details emerging drugs, market drivers like rising prevalence and innovative pipelines, and barriers such as high costs and manufacturing complexities.
Stoke Therapeutics (STOK) has completed Phase 3 enrollment for its lead program, zorevunersen, for Dravet syndrome, with plans for a rolling New Drug Application submission to the US FDA in early 2027. This milestone reinforces the importance of the program as a key near-term catalyst and could reshape the company's investment narrative. While clinical and regulatory outcomes remain central risks, the company projects significant revenue and earnings growth by 2029, with a fair value estimate indicating a 37% upside to its current price.
Biogen Inc. (BIIB) shares fell 1.32% to $205.70 on Tuesday, underperforming the broader stock market, which also saw declines in the S&P 500 Index and Dow Jones Industrial Average. This marks the second consecutive day of losses for the stock.
US private equity firm TA Associates has been selected as the preferred bidder to acquire CGBio, a regenerative medicine company from South Korea's Daewoong Group, in a deal valued at approximately 1 trillion won ($655.5 million). This development follows the collapse of earlier negotiations with IMM Private Equity. CGBio's corporate valuation was significantly boosted by a landmark exclusive supply agreement with Johnson & Johnson's orthopedic subsidiary, DePuy Synthes, for its bone graft product, Novosis.
Biogen Inc. (BIIB) is expected to continue its streak of beating earnings estimates, according to Zacks Equity Research. The company has a strong record of exceeding expectations in its last two reports, with an average surprise of 22.31%. Combined with a positive Zacks Earnings ESP of +0.22% and a Zacks Rank #3 (Hold), these indicators suggest a high probability of another earnings beat in its upcoming report on July 29, 2026.
Travere Therapeutics (TVTX) was recently removed from several Russell value and small-cap indices in late June 2026. This action could lead to forced portfolio rebalancing by index-tracking funds and reshape the company's investment narrative and risk profile, despite its core growth driver, FILSPARI, receiving expanded FDA approval in April 2026. While operational progress continues with FILSPARI for rare kidney diseases, investors are advised to consider the implications of the index removal on broader market perception and potential payer scrutiny regarding drug pricing.
Biogen Inc. (BIIB) is expected to continue its streak of beating earnings estimates, driven by its positive Zacks Earnings ESP of +0.22% and a Zacks Rank #3 (Hold). The company has a history of exceeding earnings expectations, with an average surprise of 22.31% over the last two quarters. This combination suggests a high probability of another positive surprise in its upcoming earnings report on July 29, 2026.
Biogen Inc. announced it will host an investor webcast on Tuesday, July 14, 2026, at 12:00 p.m. ET, from the Alzheimer's Association International Conference (AAIC) in London. The live webcast will feature Biogen management and will be accessible via the investors section of Biogen’s website, with an archived version available for 90 days. The announcement was made on July 7, 2026.
Jefferies has increased its price target for Biogen (BIIB) from $210 to $255. This adjustment was published on July 7, 2026, at 05:34 am EDT by MT Newswires, indicating a more optimistic outlook on the pharmaceutical company's stock by the firm.
The Amyotrophic Lateral Sclerosis (ALS) market is projected to grow significantly by 2036, driven by an increasing disease prevalence, advancements in drug development, and rising regulatory support. Key companies like Helixmith, Sanofi, and Biogen are actively developing new therapies, with several receiving Orphan Drug or Fast Track designations from the FDA. Despite challenges such as complex disease biology and high clinical trial failure rates, the focus on precision medicine and R&D investments is poised to transform the treatment landscape for ALS.
This article provides a detailed stock summary page for Biogen Inc (MEX:BIIB), covering its current stock price, key financial metrics like P/E ratio, market cap, and enterprise value. It also includes an overview of the company's business description as a biopharmaceutical firm focused on neurodegenerative and rare diseases, along with various financial strength, growth, profitability, and valuation ranks. The page highlights warning signs detected by GuruFocus and lists upcoming stock events and recent press releases related to the company.
Biogen Inc (BIIB) shares dropped 3.5% to $208.46, yet GuruFocus's GF Value continues to indicate the stock is overvalued by 8.7% compared to its intrinsic value of $191.80. The company's GF Score is 73/100, reflecting strong financial health and profitability but weak growth prospects, and its P/E ratio of 22.4x is significantly higher than its historical median. The absence of insider transactions over the last three months also suggests a cautious stance among company executives.
Biogen Inc (BIIB) shares fell 3.5% on July 6, 2026, to $208.46, but are still considered overvalued by GuruFocus's GF Value, trading 8.7% above its intrinsic value of $191.80. The company's GF Score is 73/100, indicating strong financial health and profitability but weaker growth prospects. Despite a positive year-to-date and past-year performance, the elevated P/E ratio and lack of recent insider transactions suggest caution for investors.
Vertex Pharmaceuticals announced its acquisition of Crinetics Pharmaceuticals for $10 billion, marking Vertex's largest acquisition to date. The deal includes Crinetics' commercial drug Palsonify for acromegaly, other potential blockbuster drug candidates, and a late-stage therapy for congenital adrenal hyperplasia. Following the announcement, Crinetics' shares surged 101% in after-hours trading.
